Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TACR3 | P29371 | 16/20 | 0.70 |
| ▸ | TACR2 | P21452 | 1/20 | 0.57 |
| ▸ | PDE10A | Q9Y233 | 2/20 | 0.50 |
| ▸ | DHODH | Q02127 | 2/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
| ▸ | TSHR | P16473 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3902769 | 0.91 | TACR3 (0.61) | TACR3TACR2DHODH | |
| SCHEMBL3895246 | 0.88 | TACR3 (0.64) | TACR3DHODH | |
| SCHEMBL3895251 | 0.86 | TACR3 (0.61) | TACR3TACR2 | |
| SCHEMBL4230491 | 0.85 | TACR3 (0.72) | TACR3TACR2PDE10ADHODHLMNA | |
| SCHEMBL3963611 | 0.82 | TACR3 (1.00) | TACR3TACR2DHODH | |
| SCHEMBL4232902 | 0.80 | TACR3 (0.61) | TACR3TACR2PDE10ADHODHLMNA | |
| SCHEMBL3908668 | 0.79 | DHODH (0.71) | TACR3TACR2PDE10ADHODHLMNA | |
| SCHEMBL8792622 | 0.77 | DHODH (0.72) | TACR3TACR2PDE10ADHODHLMNA | |
| SCHEMBL4475835 | 0.75 | TACR3 (0.58) | TACR3TACR2PDE10ADHODHLMNA | |
| SCHEMBL4229867 | 0.73 | PTGFR (0.60) | TACR3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1776343-B1 | QUINOLINE DERIVATIVES AS NEUROKININ RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME (GB) | 2009-03-04 | — | — | EP | disclosed |
| US-20080312274-A1 | Quinoline Derivatives as Neurokinin Receptor Antagonists | CARLING WILLIAM ROBERT | 2008-12-18 | — | — | US | disclosed |
| US-20080312274-A1 | Quinoline Derivatives as Neurokinin Receptor Antagonists | CARLING WILLIAM ROBERT | 2008-12-18 | — | — | US | disclosed |
| US-20080312274-A1 | Quinoline Derivatives as Neurokinin Receptor Antagonists | CARLING WILLIAM ROBERT | 2008-12-18 | — | — | US | disclosed |
| EP-1776343-A1 | QUINOLINE DERIVATIVES AS NEUROKININ RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME LTD. (GB) | 2007-04-25 | — | — | EP | disclosed |
| WO-2006013394-A1 | QUINOLINE DERIVATIVES AS NEUROKININ RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME LIMITED (GB) | 2006-02-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080312274-A1 | Quinoline Derivatives as Neurokinin Receptor Antagonists | TACR2, TACR3, TACR1 | TACR3 2/4885TACR2 1/4885PDE10A 2357/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.